EDINBURGH MOLECULAR IMAGING
See. Treat. Cure.
Highly Specific Cancer Targeting
Using its proprietary platform technology, EM Imaging is developing a pipeline of highly novel in vivo c-Met targeting theragnostic and optical imaging agents that will alter the landscape of precision medicine.
Pipeline
EM Imaging has a portfolio of agents addressing a number of unmet medical needs
Ongoing Clinical Studies
EM Imaging is focused on the development of fluorescent optical imaging and therapeutic agents. Our current clinical trials are detailled in a dedicated section.
Latest Press Release
Edinburgh Molecular Imaging Closes Financing
To accelerate evelopment of molecular targeted systemic radiotherapy (SR, PRRT) based on its clinical stage technology Edinburgh, United Kingdom – 17 December 2019 – Edinburgh Molecular Imaging Ltd,...
Our Latest News
Results published by Investigator on first-in-human biodistribution and first PET imaging results of [Ga-68]EMP-100 in metastatic renal cell carcinoma
This first in‑human biodistribution and imaging study for 68Ga‑EMP‑100 in metastatic renal cell carcinoma independently carried out by LMU Munich, Germany, evaluated uptake characteristics in...
Results published by Investigator on Image-guided Surgery in Penile Squamous Cell Carcinoma Patients
This pilot study suggest that c-MET is a promising target for fluorescence-guided tumour identification, with the potential to improve margin assessment in pSCC. The c-MET targeted approach proved to be compatible with lymphatic mapping performed in the same patient using multicolor fluorescence guidance based on both infrared (Cy5) and near-infrared (ICG) imaging.